Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05787795

Identifying and Characterizing Preclinical MS

The purpose of this research study is to try and identify risk factors and biologic changes that suggest that someone may go on to develop multiple sclerosis before a person has shown any symptoms of the disease.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Yale University

North Haven, Connecticut, 06473, United States

Location status: Recruiting

Location contact

Cynthia Marques

CONTACT

[email protected]

203-287-6100

Erin Longbrake, MD

PRINCIPAL_INVESTIGATOR

About this study

The purpose of this study is to try and learn how to identify multiple sclerosis (MS) before it causes any neurologic symptoms. By the time MS causes symptoms, the disease has often been causing damage under the surface for years. Because early treatment of MS helps prevent long term disability from the disease, the investigators are hypothesizing that if MS could be detected (and treated) before symptoms start, the disease might be preventable.

The investigators believe that people who go on to develop MS have changes in their immune systems long before they have symptoms. Some of these changes might be in "hidden" parts of the body, like lymph nodes or fat tissue. The investigators want to study people who have risk factors for MS to try and learn to detect very early signs of disease.

Study procedures will include:

All study participants will undergo a blood draw and an oral swab; they will also complete baseline questionnaires All study participants will be contacted approximately once per year and asked to complete some additional questionnaires All study participants may be asked to donate repeat blood/oral swab specimens or stool specimens over time on an ad hoc basis Study participants who agree will undergo additional optional procedures to study the immune system in different parts of the body.

The optional procedures include:

Lumbar punctures (to obtain spinal fluid) Tonsil biopsy Fat biopsy (to obtain fat cells) Lymph node biopsy (to obtain lymph node tissues with immune cells) Traditional brain MRI Low-field (portable) brain MRI

One in-person visit is required. There will also be annual phone/email contact, which may take up to 30 minutes The required in-person visit will take approximately 1 hour total. Anyone who agrees to donate follow up biospecimens, undergo a procedure, or undergo an MRI will have additional in-person visits Optional visits for donating biospecimens, having a procedure or getting an MRI may take longer (up to 3 hours), depending on what is happening during the visit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18+
  • Having one or more risk factors for multiple sclerosis, including one or more of the below:
  • Individuals known to have a radiologically isolated syndrome
  • Individuals with a family history of multiple sclerosis (first degree family member)
  • Individuals with personal risk factors, which are known to include smoking, obesity, Epstein Barr virus infections, Vitamin D deficiency, genetic risk score

Exclusion criteria

  • Currently pregnant
  • Diagnosis of multiple sclerosis or any ongoing, systemic autoimmune disease
  • Ongoing treatment with immunosuppressive medications

Treatment and study plan

Biological Samples

Other

blood draw, oral swab, optional stool samples, spinal fluid sample, fat biopsy, tonsil biopsy, lymph node tissue sample, MRI

Primary outcomes

  1. To build a machine learning model of risk prediction

    Time frame: ongoing prospective study

    to build a risk prediction model that estimates future risk of MS built using large datasets of biologic and clinical data collected during the study.

Secondary outcomes

  1. Individual data types collected

    Time frame: ongoing prospective study

    Microbiome data, immune phenotyping and functional analysis for blood, CSF, adipose tissue, measurement of other known and developing biomarkers of MS, patient reported health outcomes will be compiled to potentially identify early, systemic changes that are associated with a future risk of multiple sclerosis.

Study contacts

Contact information is provided by the study sponsor or research team.

Erin Longbrake, MD

CONTACT

[email protected]

860-287-6100

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Roche-Genentech

Registry information

Acronym: DREAM

Important dates

Study start
2022
Primary completion
2032
Study completion
2033
First posted
Mar 28, 2023
Registry last updated
Nov 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.